Finance
Recordati's Core Profit Rises, but Sees Bigger Fx Hit
Published by Global Banking & Finance Review®
Posted on July 29, 2025
1 min readLast updated: January 22, 2026
Add as preferred source on Google
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on July 29, 2025
1 min readLast updated: January 22, 2026
Add as preferred source on GoogleRecordati's core profit rose by 9.6%, but adverse currency movements are expected to impact revenue by 3% annually.
(Reuters) -Italian drugmaker Recordati reported on Tuesday a 9.6% rise in first-half core profit, but said adverse currency moves would have a bigger than impact than previously expected over the full year.
The pharmaceutical company's earnings before interest, taxes, depreciation and amortisation (EBITDA) for the first half of the year came in at 496.3 million euros ($572.8 million), while its adjusted net income rose 8.9% to 327.8 million euros.
While confirming its 2025 guidance, Recordati warned of a "significantly higher" impact from unfavourable currency moves, amounting to a 3% revenue hit on a yearly basis.
The pharmaceutical firm had said at the beginning of the year it expected a 1% hit from adverse currency moves.
($1 = 0.8665 euros)
(Reporting by Philippe Leroy Beaulieu in Gdansk. Editing by Mark Potter)
Recordati reported a 9.6% rise in first-half core profit.
Recordati warned of a 'significantly higher' impact from currency moves, amounting to a 3% revenue hit on a yearly basis.
The company's EBITDA for the first half came in at 496.3 million euros ($572.8 million).
Earlier in the year, Recordati expected a 1% hit from adverse currency moves, which has now increased to 3%.
The reporting was conducted by Philippe Leroy Beaulieu in Gdansk.
Explore more articles in the Finance category
